RXST · XBRL financial data

RxSight financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RXST's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	22,593	49,005	89,077	139,927	134,479
Cost of goods and services sold	18,076	27,677	35,312	40,984	31,470
Gross profit	4,517	21,328	53,765	98,943	103,009
Research and development	24,499	25,981	29,051	34,367	38,549
Selling, general and administrative	32,805	58,665	74,799	101,434	112,651
Total operating expenses	57,304	84,646	103,850	135,801	151,200
Operating income (loss)	(52,787)	(63,318)	(50,085)	(36,858)	(48,191)
Interest expense	3,682	4,946	3,308	21	19
Income tax expense (benefit)	8	9	20	50	66
Net income (loss)	(48,688)	(66,756)	(48,608)	(27,455)	(38,944)
Earnings per share, basic USD per share	(3.57)	(2.41)	(1.41)	(0.71)	(0.95)
Earnings per share, diluted USD per share	(3.57)	(2.41)	(1.41)	(0.71)	(0.95)
Weighted average shares, basic thousands of shares	13,625	27,662	34,455	38,868	40,851
Weighted average shares, diluted thousands of shares	13,625	27,662	34,455	38,868	40,851

Fiscal years (RXST's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	24,361	11,834	9,692	16,706	19,949
Short-term investments	134,971	93,968	117,490	220,517	208,179
Accounts receivable	4,862	10,956	20,281	30,050	23,383
Inventory	8,032	14,835	17,421	22,009	31,559
Prepaid and other current assets	4,069	2,962	3,523	4,541	4,389
Total current assets	176,295	134,555	168,407	293,823	287,459
Property and equipment, net	11,217	10,138	10,841	12,413	13,056
Right-of-use asset	4,284	3,943	2,444	11,217	9,959
Total assets	192,721	150,164	182,550	318,563	311,814
Accounts payable	1,689	2,595	3,863	4,544	5,296
Accrued liabilities	7,859	12,672	15,239	20,358	19,795
Total current liabilities	11,077	17,237	20,903	25,876	26,253
Lease liability, non-current	3,625	2,813	1,093	11,216	9,813
Total liabilities	54,479	60,262	22,188	37,325	36,131
Accumulated deficit	(479,276)	(546,032)	(594,640)	(622,095)	(661,039)
Total stockholders' equity	138,242	89,902	160,362	281,238	275,683
Total liabilities and equity	192,721	150,164	182,550	318,563	311,814
Common shares outstanding (cover page) thousands of shares	27,418	33,776	36,988	40,491	41,266

Fiscal years (RXST's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(48,688)	(66,756)	(48,608)	(27,455)	(38,944)
Stock-based compensation	7,575	11,397	15,746	24,635	31,612
Depreciation and amortization	3,975	3,884	4,078	3,575	3,266
Net cash from operating activities	(44,708)	(58,850)	(41,593)	(16,946)	(15,511)
Purchases of property and equipment	1,940	2,393	4,814	5,440	3,830
Net cash from investing activities	(81,907)	39,950	(22,129)	(99,311)	16,889
Proceeds from issuing common stock	12,400	1,778	9,473	20,816	3,951
Net cash from financing activities	137,342	6,332	61,524	123,319	1,863
Net change in cash	10,717	(12,577)	(2,192)	7,053	3,243

SIC 3851 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3851 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Quarter
RxSight	66,717	24,546	45,216*	41.9M	Q3 FY26 10-QSep 30, 2026
Bausch & Lomb	513,000	1,375,000	233,000*	357.5M	Q3 FY26 10-QSep 30, 2026
Staar Surgical	148,579	93,535	19,690*	50.1M	Q2 FY26 10-QJul 3, 2026
National Vision Holdings	35,998	498,805	8,110*	79.1M	Q2 FY26 10-QJul 4, 2026
Warby Parker	292,674	235,511	29,618*	not reported	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.